Setting research priorities in partnership with patients to provide patient-centred urological cancer care by Rossi, S.H. et al.
This is a repository copy of Setting research priorities in partnership with patients to 
provide patient-centred urological cancer care.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/145593/
Version: Accepted Version
Article:
Rossi, S.H., Fielding, A., Blick, C. et al. (3 more authors) (2019) Setting research priorities 
in partnership with patients to provide patient-centred urological cancer care. European 
Urology. ISSN 0302-2838 
https://doi.org/10.1016/j.eururo.2019.03.008
Article available under the terms of the CC-BY-NC-ND licence 
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Setting research priorities in partnership with patients to provide patient-centred urological 
cancer care 
 
Sabrina H. Rossia, Alison Fieldingb, Christopher Blickc, Catherine Handforthd, Janet E. Brownd,*, Grant 
D. Stewarta,*  
 
(a) Department of Surgery, University of Cambridge, Addenbrooke's Hospital, Cambridge 
Biomedical Campus, Cambridge, UK 
(b) National Cancer Research Institute Bladder and Renal Cancer Clinical Studies Group  
(c) Harold Hopkins Department of Urology, Royal Berkshire Hospital, Reading, UK 
(d) Academic Unit of Clinical Oncology and Cancer Clinical Trials Unit, Weston Park Hospital, 
University of Sheffield, UK 
*Joint senior authors 
 
Corresponding author: 
Mr G.D. Stewart 
Department of Surgery,  
University of Cambridge,  
Addenbrooke's Hospital,  
Cambridge Biomedical Campus, Cambridge, UK 
Email: gds35@cam.ac.uk 
 
  
There is a growing body of work advocating that research funding should be matched to the societal 
burden of a disease, which goes beyond simple mortality measures. Renal cell carcinoma (RCC) is a 
good example of this problem. RCC contributes to a greater average number of years of life lost (a 
measure of cancer burden dependent on patient age at death and the number of deaths at each 
age) than other urological, colorectal and haematological cancers (1). Despite its increasing 
prevalence, RCC receives a disproportionately small fraction of the cancer research budget across 
the UK, USA and Australia (1,2). It follows that research priorities should be identified using 
transparent and rigorous methodology, to maximise output, avoid research waste and enable 
international collaboration (3). Furthermore, there is a well-documented discrepancy between the 
prioritisation of the research agenda by patients and researchers (4). As such, patient and carer 
participation in priority setting is crucial. The James Lind Alliance (JLA) was developed to facilitate 
researcher, carer and patient collaboration within Priority Setting Partnerships using standardised 
methods (5). A number of national and international organisations, including the UK National Cancer 
Research Institute (NCRI) and the National Institute for Health Research (NIHR), have emphasised 
consumer participation in priority setting as key goals within their strategic agenda and they 
collaborate with the JLA to achieve this (6,7). This has sparked international efforts to establish 
robust research priorities in a number of cancer types. A highly successful initiative identified 
research gaps in breast cancer in 2008 and was updated in 2013 (8). This work has led to tangible 
research advances, and the source manuscript has been cited nearly 150 times (8). This has been 
followed by research gap analyses in other disease areas. including colorectal cancer. 
 
We established the Renal Cancer Gap Analysis Collaborative with the aim of developing a consensus 
statement regarding research priorities in RCC. The collaborative was composed of clinicians, 
researchers, patients and carers and the results have been published in a recent issue of European 
Urology Focus (9). We included the full spectrum of RCC from curative to metastatic disease. The 
project consisted of two phases: in phase I, research gaps (RGs) were identified and in phase II, RGs 
were scored through a multistep Delphi process to achieve consensus regarding the most critical. In 
phase I, 44 key opinion leaders from five different European countries (UK, Portugal, France, Sweden 
and the Netherlands) submitted literature reviews on 24 key themes, across the RCC disease 
spectrum. The reviews were summarised in plain English and distributed amongst patients with RCC 
and carers, via the charity Kidney Cancer UK. Group discussions involving disease experts and 
patients as well as detailed one-to-one interviews with patients were undertaken. Following three 
consensus meetings amongst clinicians and patients, 39 RGs were identified for inclusion in phase II. 
Subsequently, experts (N=82) scored these gaps on a 9-point scale (1-3: Not important; 4-6: 
Important; 7-9: Critical) during three online Delphi surveys. The surveys aimed to reach a consensus, 
ĚĞĨŝŶĞĚĂƐш ? ?йĂŐƌĞĞŵĞŶƚďǇĞǆƉĞƌƚƐ ?Patients reviewed the results of the Delphi surveys and 
provided feedback. This work has resulted in the identification of fourteen crucial RGs, across a 
broad range of RCC themes (Figure 1).  
 
Patient and carer involvement throughout this work was critical. Indeed, our work identified 
different RGs to a previous RCC initiative not directly involving patients, which placed greater 
emphasis on understanding tumour biology, genomic and epigenetic factors and epidemiology (10). 
Conversely, initiatives in which patient participation was central, uncovered RGs across similar 
overarching themes highlighted by our work, including early detection, personalised patient 
management and follow up (11). Research gaps deemed crucial in our work focus on maximising 
quality of life and managing often overlooked groups, such as individuals with reduced performance 
status and rarer RCC subtypes. Furthermore, the inclusion of qualitative data obtained through 
patient interviews was crucial in highlighting important RGs pertinent to topics which are often 
overlooked by researchers; such as patient education, improved patient-doctor communication, 
mental health, the influence of social media and support groups. Independent patient surveys have 
highlighted the significance of these issues for patients with RCC and carers (12). 
 Enabling effective patient/carer input requires investment from both clinicians and consumers. With 
appropriate training and support, expert patients can develop a deep understanding of the research 
process whilst retaining a connection to the realiƚŝĞƐŽĨƉĂƚŝĞŶƚƐ ?ĐŽŶĐĞƌŶƐ. It remains important to 
have wider consultations reaching a cross-section of the patient community. For this, patients need 
plain language summaries and facilitators able to guide deeper discussions. Patient groups and 
charities are a useful means to achieve this input. Technology brings opportunities for involving 
patients much more easily. Established patient online networks can offer rapid access to patients 
willing to undertake surveys and review content and a conduit to communicate about research 
design, delivery and dissemination. Engagement with patient advocates with good links to these 
networks provides an ongoing real-time insight into emerging issues impacting research needs. 
Smartphone technology enables PROMS and quality of life data to be easier to collect. Consultation 
with a broader selection of patients who may not be internet enabled is important and can be 
facilitated by both clinicians and patient networks.  
 
The work described in ƚŚŝƐŵŽŶƚŚ ?ƐŝƐƐƵĞŽĨEU Focus represents the most contemporary and 
systematic priority setting initiative in RCC to date, focusing on a European setting (9-11). Although 
the majority of participants represent a UK and European setting, a Canadian project published in 
European Urology identified overlapping research priorities suggesting these may be common to all 
Western settings (11). Further research should focus on fostering international collaborations to 
bridge the research gaps identified; as well as evaluating geographical variation between 
international research needs. The process of priority setting should be continuous as research 
advances in one domain may shift the future balance of relative importance for patients and 
researchers. The identification of research priorities, involving consumer representatives and using 
standardised methods, should be a key goal for all cancer types. 
 
 
 
 
 
 
Figure 1: The fourteen critical research gaps identified, and how these are aligned to the main 
themes/stages along the RCC patient journey, from small renal masses to metastatic disease. The 
ĨŝŐƵƌĞĚĞŵŽŶƐƚƌĂƚĞƐƚŚĞƉĞƌĐĞŶƚĂŐĞŽĨƉĂƌƚŝĐŝƉĂŶƚƐƚŚĂƚƐĐŽƌĞĚƚŚĞƌĞƐĞĂƌĐŚŐĂƉĂƐ ?ƌŝƚŝĐĂů ?ŝŶƚŚĞ
Delphi survey. The asterisks indicate during which iteration consensus was achieved (i.e. *= 
consensus achieved in the first survey; **= second survey; ***=third survey). 
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